source
- Carvykti shows 5-year survival in half of multiple myeloma patients in Phase 2 studyJohnson & Johnson and Legend Biotech reported that 10 of the 20 multiple myeloma patients treated with a single dose of Carvykti remained alive after a median follow‑up of 60.7 months, representing…
- Biomanufacturers Redesign Processes to Blend Emergency Vaccine Readiness with Commercial FlexibilityManufacturers are overhauling their production methods to simultaneously improve rapid vaccine deployment for future health crises and maintain flexible, commercially viable manufacturing networks…